Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 68 | UKINETS2019 | Next issue

17th Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2019

Birmingham, UK
02 Dec 2019 - 02 Dec 2019

Card image cap
The Conference is your opportunity to join fellow clinicians, scientists, nurses and allied health care workers involved in the care and service of neuroendocrine tumour (NET) patients.

ea0068p1 | Abstracts | UKINETS2019

Size still matters for appendiceal neuroendocrine tumours (aNETs)

Alabraba Edward , Malik Hassan , Banks Melissa , Pritchard Mark , Cuthbertson Daniel , Poston Graeme , Fenwick Stephen

Background: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy, are indolent and rarely recur.Methods: We retrospectively analysed patients diagnosed with aNETs and entered prospectively into our tertiary referring centre’s NET database between 1990 and 2016.Results: 102 patients (F:M ratio of 1.04:1) presented with aNET at a median age of 39.4 (range 16.3–81.1) years. Average ...

ea0068p2 | Abstracts | UKINETS2019

The role of Thymosin Beta 4 as an autocrine mitogen in neuroendocrine tumours

Beaumont Nicholas , Liang Shuxin , Cuenco Joy , Marotta Davide , Mandair Dalvinder , Balasundaram Ponni , Semkova Mariya , Waugh Mark , Srirajaskanthan Raj , Pereira Stephen , Caplin Martyn , Lu Xiufang , Hsuan Justin

Neuroendocrine tumours (NETs) occur in multiple tissues and vary widely in clinical behaviour. Up to 70% of diagnosed patients have elevated circulating levels of chromogranin A, the only serum marker commonly used in clinical practice. However, its low sensitivity and the identification of confounding factors that compromise specificity have raised the need for additional or alternative markers for disease detection and management. Here we aimed to discover candidate NET mark...

ea0068p3 | Abstracts | UKINETS2019

The effects of somatostatin analogues on HbA1c and BMI in the treatment of neuroendocrine tumours

Patel Kishen , Nahar Ananda , Ventakraman Hema , Elhassan Yasir , Shah Tahir , Ayuk John

Long acting somatostatin analogues (SSA) such as Sandostatin LAR and Lanreotide Autogel are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.Methods:...

ea0068p4 | Abstracts | UKINETS2019

Appendiceal GCCs have a poor prognosis despite completion surgery as recommended by ENET guidelines

Alabraba Edward , Malik Hassan , Banks Melissa , Pritchard Mark , Cuthbertson Daniel , Poston Graeme , Fenwick Stephen

Background: Current ENET guidelines inform our management of GCCs but we still have poor understanding of how these tumours behave in clinical practice.Methods: We retrospectively analysed patients diagnosed with GCCs and entered prospectively into our tertiary referring centre’s NET database between 1990 and 2016.Results: 41 patients (F:M ratio of 1.28:1) presented with GCC at a median age of 61 (range 27–79) years. Aver...

ea0068p5 | Abstracts | UKINETS2019

Development of a mobile app for patients with neuroendocrine neoplasms: a collaborative project between United Kingdom NET Society and Neuroendocrine Tumour Patient Foundation

Bouvier Catherine , Ramage John , Newell-Price John , Virk Jeevan , Allan Ronny , Verey Peter , Alaghband Nader , Srirajaskanthan Raj

Background: Symptom management is a cornerstone of clinical care, particularly for patients with cancer. However, often patient’s symptoms go undetected by health care providers between clinic visits. Mobile health applications are increasingly used in oncological care to support cancer patients.Aims: To develop a patient focussed mobile application to enable patients to track symptoms, record quality of life, communicate with their clinical teams a...

ea0068p6 | Abstracts | UKINETS2019

Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms: experience from a European Neuroendocrine Tumour Society centre of excellence

Nuttall Christina , Lamarca Angela , McNamara Mairead , Barriuso Jorge , Lawrance Jeremy , Mullan Damian , Mansoor Was , Valle Juan , Hubner Richard

Background: Hepatic arterial embolisation (HAE) is a recommended treatment option for patients with neuro-endocrine neoplasms (NENs) and liver metastasis. We aimed to describe outcomes after HAE for NENs at a single United Kingdom centre and investigate the influence of tumour characteristics.Methods: Retrospective analysis of sequential patients with NENs undergoing HAE at The Christie NHS Foundation Trust between 2004 and 2018. Primary end points were ...

ea0068p7 | Abstracts | UKINETS2019

pNETs (Pancreatic Neuroendocrine tumours) in MEN1 (Multiple Endocrine Neoplasia): a single centre case series

Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Geh Ian , Shetty Shishir , Shah Tahir , Ayuk John

Introduction: MEN1 associated pNETs share a unique profile in comparison to sporadic pNETs. The literature on pNETs in MEN1 is evolving with on-going ambiguities in presentation and management. We present a case series of MEN1 associated pNETs from a tertiary centre of excellence for NETs in the UK.Methods: Institutional NET database was used for retrospective data analysis for all patients with pNETs associated with MEN1.Results: ...

ea0068p8 | Abstracts | UKINETS2019

Audit of the appropriateness and outcomes of 24-hour urinary 5-HIAA testing in a UK general hospital

Higginson Kieren , Pritchard D Mark

Introduction: Some functional neuroendocrine tumours (NETs) secrete serotonin, leading to the symptoms of carcinoid syndrome (e.g. diarrhoea and flushing). In this condition, increased urinary concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) are often detected. Measurement of 24-hour urinary 5-HIAA is therefore used to investigate patients with confirmed or suspected carcinoid syndrome. We sought to evaluate the appropriateness and effectiveness o...

ea0068p9 | Abstracts | UKINETS2019

Gastric neuroendocrine neoplasms: clinical management and outcomes in a cohort of 54 patients

Victor Alexandra , Ramage John Keith , Cope Jack , Maclean Rory , Hayee Bu , Martin Wendy , Cananea Elmie , Clement Dominique , Srirajaskanthan Raj

Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10–20% can be type 3 or type 4 Gastric NENs.Methods: A retrospective review performed of 54 patients with gastric NENs referred to a tertiary centre during 2014 to 2019.Results: Of the 54 cases referred, 45 were type 1 gastric NENs and the 9 were type 3 Gastric NENs. Of the 45 type 1 gastric N...

ea0068p10 | Abstracts | UKINETS2019

Type III gastric neuroendocrine neoplasms: moving towards less-extensive resections in selected cases?

Exarchou Klaire , Kameniarz Lukasz , Victor Alexandra , Khan Mohid , Srirajaskanthan Raj , Mandair Dalvinder , Ramage John , Caplin Martyn , Pritchard David Mark , Toumpanakis Christos

Background: Type III gastric neuroendocrine neoplasms (g-NEN) are usually lesions of higher grade and often associated with loco-regional and distant metastases. Guidelines recommend partial or total gastrectomy with local lymph node resection. Data for less-extensive resections are limited.Aim: To assess whether advanced endoscopic excision [Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD)] or localized surgical approach (wed...

ea0068p11 | Abstracts | UKINETS2019

Can determination of radiological tumour volumes and tumour growth rates better determine response to somatostatin analogues in slowly growing neuroendocrine tumours?

Hazeldine Thomas , Braimah Fatimah , Brown Peter , Anthoney Alan

Introduction: Somatostatin analogues (SSA) are a cornerstone in the treatment of neuroendocrine tumours. Two clinical trials have defined the disease control effect of these treatments; the PROMID study of Octreotide LAR v’s placebo, median time to tumour progression (TTP) 14.2 m v’s 6.0 m, and the CLARINET study (Lanreotide v’s placebo), median progression free survival (PFS) 31 m v’s 18 m. In every day practice, however, many neuroendocrine tumours commen...

ea0068p12 | Abstracts | UKINETS2019

Systemic chemotherapy for inoperable Goblet Cell Adenocarcinomas (GCAs)

Barriuso Jorge , Lamarca Angela , Martin Amy , Chakrabarty Bipasha , Clouston Hamish , Mullamitha Saifee , McNamara Mairead , Marti-Marti Francisca , Hubner Richard , Saunders Mark , O'Dwyer Sarah , Braun Michael , Valle Juan

Background: Appendiceal GCAs (previously known as Goblet Cell Carcinoids) are considered to have an unpredictable behaviour; even in node-negative patients, metastases mainly local to the adjacent peritoneum are seen. The systemic chemotherapy (scx) is often borrowed from colon cancer regimens. We designed a retrospective study with the aim of describing the use of scx in these rare malignancies in our institution.Methods: Data from all consecutive cases...

ea0068p13 | Abstracts | UKINETS2019

Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome: a single centre study from a centre of excellence

Davis LM , Nicou N , Martin W , Corcoran B , Mulholland N , Srirajaskanthan R , Ramage J , Wendler O , Vivian G

Introduction: Perioperative mortality of patients who undergo heart valve surgery for carcinoid heart valve disease (CHVD) has been observed to be high (5–10%). We investigated whether peptide receptor radiotherapy (PRRT) with Lutetium-177 Dotatate can be used safely in patients with neuroendocrine neoplasms (NEN) and CHVD and if there is an associated survival advantage by reducing overall exposure of the valves to high doses of vasoactive peptides.<p class="abstext"...

ea0068p14 | Abstracts | UKINETS2019

Liver embolisation for patients diagnosed with neuroendocrine neoplasms: systematic review and meta-analysis of the literature

Kanabar Rahul , Barriuso Jorge , McNamara Mairead , Mansoor Was , Hubner Richard , Valle Juan , Lamarca Angela

Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN), especially in the presence of carcinoid syndrome. It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs.Methods: Eligible studies (identified...

ea0068p15 | Abstracts | UKINETS2019

Surgical correction of carcinoid heart disease improves liver function, 5HIAA levels and subjective assessment of carcinoid symptoms

Shah Husnain , Sagar Vandana , Venkataraman Hema , Steeds Rick , Rooney Stephen , Shah Tahir

Introduction: Neuroendocrine tumours of the gastrointestinal tract often cause carcinoid syndrome and in advance cases carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and eventually valve incompetence. Most cases involve the tricuspid valve +/− pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve...

ea0068p16 | Abstracts | UKINETS2019

Clinical characteristics and outcomes of 23 patients with insulinoma: a single centre retrospective observational study 2011–2018

Healy Ultan , Tadman Michael , Weaver Andrew , Fryer Eve , Bailey Adam , Patel Neel , Boardman Phil , Soonawalla Zahir , Pal Aparna , May Christine JH , Thakker Raj V , Grossman Ashley B , Jafar-Mohammadi Bahram

We report a retrospective, single centre observational study to determine the characteristics and outcomes of pancreatic insulinoma. Interrogation of the Oxford NET database, a departmental database of new NET MDT referrals since 2011 (n = 1059), revealed 23/1059 (2.1%) patients with insulinoma diagnosed and treated between 2011 and 2018. Patient records were reviewed and data was captured on demographics, presentation, investigations, treatments and outcomes: 15/23 (...

ea0068p17 | Abstracts | UKINETS2019

Single Centre Experience of PRRT with 90Y DOTATATE in metastatic or unresectable paragangliomas

Ravindran Wishvan , Morganstein Daniel , Du Yong

Background: Paragangliomas are rare neuroendocrine tumours arising in the autonomic nervous system, which can secrete excess catecholamines, causing cardiovascular complications. Malignancy occurs in up to 23% of paragangliomas, resulting in a poor prognosis with a 5-year mortality of 43–63%. There’s a limited evidence base for their treatment, with no official guidelines. Peptide Receptor Radionuclide Therapy (PRRT) is a proven treatment for neuroendocrine tumours o...

ea0068p18 | Abstracts | UKINETS2019

Frequency and causes of elevated fasting plasma concentrations of a panel of gut hormones in routine clinical practice

Butler Olivia , Mekhael Monica , Ahmed Arslan , Pritchard D Mark

Introduction: In the UK, the fasting plasma concentrations of a panel of gut hormones (vasoactive intestinal peptide (VIP), gastrin, pancreatic polypeptide, glucagon and somatostatin as well as chromogranin A) are frequently measured during the evaluation of patients who have confirmed or clinically suspected neuroendocrine tumours (NETs). However, elevated concentrations of these hormones are sometimes also detected in patients who have no other evidence of a NET. We sought t...

ea0068p19 | Abstracts | UKINETS2019

Endoscopic management and outcomes of gastro-duodenal neuroendocrine tumours

Victor Alexandra , Pizanias Michail , Gulati Shraddha , Gunasingham Nishmi , Ramage John Keith , Haji Amyn , Srirajaskanthan Raj

Background: Gastric and duodenal neuroendocrine tumours are increasing in incidence. ENETS guidelines suggest endoscopic resection of type 1 gastric NENs over 10 mm and consider endoscopic resection for duodenal NENs. However, the endoscopic techniques are not clearly mandated. There, is evidence to suggest endoscopic mucosal dissection has higher incidence of R0 resections compared with polypectomy or EMR alone. We have reviewed our data of endoscopic resection of gastro-duod...

ea0068p20 | Abstracts | UKINETS2019

A retrospective study of FDG uptake in pathologically confirmed DIPNECH and its contributing variables

Odedra Krishan , Shah Tahir , Geh Ian , Hughes Simon

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is documented as a pre-malignant condition by the World Health Organisation. Patients with pulmonary nodules typically undergo 5′-18fluoro-deoxy-D-glucose (FDG) positron emission tomography combined with computed tomography (PETCT) for further diagnostic investigation. DIPENCH is widely accepted as an FDG negative pathology. The purpose of this analysis was to a...

ea0068p21 | Abstracts | UKINETS2019

Mitotane treatment in adrenocortical cancer: getting to and staying in the therapeutic range, toxicity and outcomes

Otter Daniel , Anthoney Alan

Mitotane is an inhibitor of adrenal steroidogenesis with cytostatic activity used in the adjuvant and palliative treatment of adrenocortical cancer. Evidence shows that achieving a therapeutic range of between 14 and 20 mg/l is associated with optimal disease control whereas blood levels above this can result in more severe gastrointestinal and neurological toxicity. Therapeutic drug monitoring is available but in real life achieving and remaining within the ideal range can be...

ea0068p22 | Abstracts | UKINETS2019

Sheffield experience of administering Lutathera as a day case treatment

Maynard Alec , Hill Steven , Hallam Anna , Sabbagh Ahmad , Brown Colleen , Munir Alia , Newell-Price John , Wadsley Jonathan

Introduction: Lutetium-177 Oxodotreotide (Lutathera) is a targeted molecular radiotherapy treatment for advanced, inoperable, progressive neuro-endocrine tumours. We present our experience of Lutathera therapy with particular focus on our experience implementing treatment as a day-case procedure, and assessment of adherence to treatment quality standards surrounding the administration.Aims: To assess safety of Lutathera as a day-case treatment.<p cla...

ea0068p23 | Abstracts | UKINETS2019

Effects of debulking surgery, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) on quality of life in patients with metastatic ileal and pancreatic neuroendocrine tumours (NETs)

Sinclair Adam , Tanno Lulu , Jarvis Emma , Ramsey Emma , Naheed Salma , Armstrong Thomas , Takhar Arjun , Knight John , Stedman Brian , Modi Sachin , Bryant Timothy , Breen David , Nolan Luke , Al-Mrayat Ma'en , Pearce Neil , Cave Judith

Neuroendocrine tumours (NETs) are a heterogenous group of tumours that arise from neuroendocrine cells throughout the body. Debulking surgery is offered to patients with metastatic NETs and is recommended in the ENETS guidelines. This study was undertaken to evaluate the impact of debulking surgery and liver directed therapy (TACE, TAE) in metastatic NETs, on quality of life (QoL). Prospective longitudinal cohort study was undertaken at University Hospital Southampton. Patient...

ea0068p24 | Abstracts | UKINETS2019

Improving diagnosis times as part of the transformation of the South Wales NET Service

Amin Kapish , Gruber Mei-Yin , Shayan-Arani Holleh , Taylor Rebecca , Powell Catherine , Cook Katherine , Benny Ankita , Ng Sheryl , Christian Adam , Khan Mohid S

Background: Transformation of the South Wales NET service in late 2017 introduced new specialised staff, gastroenterology-led clinics and MDTs with a particular emphasis on educating referring specialties on NETs. Data has shown patient experience, satisfaction rates, quality of life and gastrointestinal symptom scores have all improved. This study aims to describe findings from new NET service data for: referrals into the service, diagnosis times after symptoms, and initial s...

ea0068p25 | Abstracts | UKINETS2019

(Non)Functioning neuroendocrine tumours in 18F-FDG PET–CT

Ferreira Clara , Cullis James

Neuroendocrine tumours (NETs) are distinctive tumours which arise from cells which have neural and hormonal origins. Gastroenteropancreatic tumours (GEP) are the most common clinically encountered NETs. Imaging has a lead role in the evaluation of these tumours – detection, staging and follow-up. It is also known that PET–CT with 18F-FDG has a limited value in well-differentiated NETs. This study was performed to evaluate the clinical value of 18</sup...

ea0068p26 | Abstracts | UKINETS2019

The incidence of additional primary malignancies in patients with GEP-NETs

Gohil Shailesh , Noble Sophie , Iwuji Chinenye , Levy Miles

Background: When seeing patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in clinic, we noticed that a significant proportion of our patients also had additional primary malignancies. This observation was also raised by patients at our local NET Patient Foundation support group. The idea that patients with GEP-NETs are more prone to additional malignancies is supported in the literature therefore we wanted to determine the proportion of our patients who ha...

ea0068p27 | Abstracts | UKINETS2019

The impact of telotristat in the west and east of Scotland

Gibson Katie , Wotherspoon Irene

Explosive, multiple episodes of diarrhoea are common in patients with neuroendocrine neoplasms affecting around 30% of the patient population. This is combination with other symptoms such as red, dry flushing and wheezing constitute carcinoid syndrome. This syndrome can have a devastating effect on patients impacting upon all aspects of their being. Somatostatin analogues alone can be successful in the management of diarrhoea however in some cases this is inadequate. In 2018 T...

ea0068p28 | Abstracts | UKINETS2019

Paraganglioma in a patient with cyanotic congenital heart disease

Umme Rubab , Jenkins Petra , Purewal Tejpal , Sharma Dushyant , Hegde Pallavi

Introduction: Phaeochromocytoma (PHAEO) and paraganglioma (PGL) are neuroendocrine tumors arising from neural crest-derived cells either in the adrenal gland (PHAEO) or along the central sympathetic and parasympathetic chains (PGL), including the carotid body. There is convincing evidence linking hypoxia pathways with development of PHAEO/PGL especially with genetic susceptibility. Association between PHAEO and PGL and cyanotic congenital heart disease (CHD) are well recognise...

ea0068p29 | Abstracts | UKINETS2019

Normal patterns of pancreatic uptake on 68Ga-DOTA PETCT

La Torre Guglielmo , Hughes Simon

DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)−peptide (DOTA peptide) seen on positron emission tomography combined with computed tomography (68Ga-DOTA PETCT) has been proven to be one of the most accurate methods of imaging NETs. The first stage in the accurate reporting and utilising DOTA PETCT is a clear understanding of the normal patterns. PNETs can present with focal DOTA peptide uptake on imaging. We present preliminary data of a retros...

ea0068p30 | Abstracts | UKINETS2019

Nutrition in patients with gastro-entero-pancreatic (GEP) neuroendocrine tumours (NETs) and NETs of unknown primary

Batchelor Emily , Gibson Katie , Wall Lucy

Background: Patients with low grade GI tract (GEP) neuroendocrine tumours and low grade neuroendocrine tumours of unknown primary (LG NETs) often live for many years even in the context of advanced disease. Their nutritional status is important to maintain wellbeing. Both the tumour and its treatment can potentially affect nutritional status.Method: Patients attending routine follow up appointments with the NET team in Edinburgh were invited to participa...

ea0068p31 | Abstracts | UKINETS2019

Transformation of non-functional metastatic pancreatic neuroendocrine tumour to functional insulinoma; a rare but recognised phenomenon

Anguelova Lia , Healy Ultan , Tadman Michael , Weaver Andrew , Fryer Eve , Patel Neel , Boardman Phillip , Soonawalla Zahir , May Christine , Pal Aparna , Grossman Ashley , Jafar-Mohammadi Bahram

We present the case of a 54-year-old woman with known metastatic non-functional pancreatic NET since 2004 that developed new debilitating recurrent hypoglycemia in 2013. The patient presented in 2004 with disseminated malignancy. Radiology revealed a large pancreatic mass associated with multiple liver lesions and abdominal lymphadenopathy. Liver biopsy confirmed well differentiated NET. Initial treatment with cisplatin etoposide chemotherapy was poorly tolerated and discontin...

ea0068p32 | Abstracts | UKINETS2019

A rare case of a left atrium paraganglioma – case report

Popescu Florentina Luiza , Bhabra Moninder , Kalkat Maninder

Cardiac paraganglioma is one of the most infrequent primary cardiac tumours, with <50 cases reported in the literature. Left atrium is the most common location. This is a case of a 57-year-old gentleman who presented with 7 year history of gradually increasing cranial perspiration, irritability, anxiety, unexplained feelings of fear, facial erythema, hypertension and atrial fibrillation. Following investigations of atrial fibrillation, a cardiac MRI scan revealed a mass be...

ea0068p33 | Abstracts | UKINETS2019

Confusion in a patient with Carcinoid syndrome

D'Arcy Robert , McCance David , Johnston Brian , Eatock Martin , Wallace Ian , Graham Una

We present a 66 year old man with a metastatic small bowel neuroendocrine tumour managed with resection of primary in 2011 and subsequent somatostatin analogue therapy. In 2018 disease progressed requiring right ureteric stenting due to extrinsic nodal compression. Three weeks later he presented with sweats, pyrexia and elevated inflammatory markers. Multiple blood and urinary cultures were clear. CT imaging, MRI spine and echocardiogram did not identify a source of sepsis. Ur...

ea0068p34 | Abstracts | UKINETS2019

Neuroendocrine breast metastases: difficulties in interpretation of pathology and distinction from breast cancer

Kayani Mahaz , Anthoney Alan , Slater Rebecca Milican

Neuroendocrine tumours presenting in the bronchial or gastrointestinal tract often present with metastatic disease. Whereas well recognised sites of metastases include liver, lymph nodes and bones, they can also arise in unusual locations sometimes causing difficulties in diagnosis. The breast is an uncommon site for neuroendocrine tumour metastasis with estimates that it represents 0.1% of all breast tumours. Due to the low incidence of these neoplasms and due to difficulties...

ea0068p35 | Abstracts | UKINETS2019

How does exercise affect the quality of life in cancer patients? A literature review

McSweneey Aisling , Dalton-O'Connor Anne

Aim: The purpose of this literature review aims to critically analyse how exercise affects quality of life (QoL) in cancer patients. The initial idea for this review was to focus on exercise and neuroendocrine tumours (NETs). As there is lack of evidence in this field, it meant a greater and widened search lead to focusing on solid tumour types as they are the most similar to NETs.Method: Methodology used to conduct this review was by using the Preferred...

ea0068p36 | Abstracts | UKINETS2019

Two case reports of preserved endocrine and exocrine function in VHL patients with extensive pancreatic cysts

El Sayed Ahmed , Boharoon Hessa , Alsafi Ali , Preitner Nadia , Kosicka-Slawinska Monika , Brady Angela , Hill Peter , Tan Tricia

Von Hippel-Lindau (VHL) disease is an inherited tumour syndrome, caused by a mutation in the VHL tumour suppressor gene encoding the VHL protein. Patients are prone to cysts and neuroendocrine tumours in the pancreas and other benign and malignant neoplasms. Pancreatic cysts occur in approximately 70% of VHL patients. We describe two cases of VHL disease with extensive multi-cystic changes affecting the whole pancreas, both patients had deletions of exon 2–3 of the VHL ge...

ea0068p37 | Abstracts | UKINETS2019

Practicality of setting up a Lutetium peptide therapy service

Farhad Mustafa , Chotai Heena , Ganatra Rakesh , Rowley Lisa

Patients with neuroendocrine disease now have the option of having peptide receptor radionuclide therapy (PRRT) for both symptomatic treatment and reducing disease progression. Lutetium (177Lu) oxodotreotide is funded centrally in the UK and several sites have recently begun to provide the treatment for their patients. There are, however, several logistical, operational and regulatory obstacles which must be navigated to ensure the service is both safe and efficient...